Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2. fázis

A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses

A legfontosabb adatok

Ki végzi
SynAct Pharma Aps
Hol
Bosznia-Hercegovina, Montenegró, Szerbia és Új-Zéland11 helyszín, 4 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
96 fő, tervezett
Kezdés
2026. máj. 1.
Várható befejezés
2027. aug. 1.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • AP1189, 100 mg
  • Placebo
A regiszteradat frissítve
2026. július 28.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • Written informed consent has been obtained prior to initiating any study-specific procedures
  • Expected respiratory viral infection, and positive for either SARS-COV-2, Influenza A or B, or RSV as confirmed by a bedside LAF test, qualitative PCR, or quantitative PCR (Q-PCR)
  • Hospitalized with respiratory insufficiency expected to be caused by respiratory viral infection defined by SpO2 ≤ 93 % on ambient air or supplementary oxygen supply via nasal catheter or facial mask (WHO Clinical Progression Scale score 5 or 6). Or in participants with hypercapnic respiratory failure (usually due to COPD) the SpO2 threshold is SpO2 ≤ 85 %
  • Duration of disease from first symptom< 15 days before enrolment
  • Females of childbearing potential using reliable means of contraception or are post-menopausal or are surgically sterilized
  • Females of childbearing potential with a negative pregnancy test at screening and baseline
  • As the morbidity and mortality of respiratory infections are many fold increased in vulnerable participants, vulnerable participants are not excluded but included as subgroups
  • Screened within 24 hours of hospital admission to the hospital, or within 24 hours of receiving a patient, if the patient is transferred from another hospital or another hospital department due to respiratory distress

Ki nem vehet részt

  • Participating in other drug clinical trials
  • Participants who have initiated treatment within 3 months prior to screening with immunosuppressive or immunomodulatory treatments for chronic autoimmune diseases. Administration of steroids or other immunosuppressive medicines implemented as standard-of-care for the treatment of the respiratory viral infection is acceptable. Asthma/COPD participants are allowed to use their habitual inhalation spray containing adrenocortical hormone
  • Any condition that in the view of the screening physician would suggest that the participant is unable to comply with study protocol and procedures
  • Already meeting any component of the primary composite endpoint at screening, defined as the presence of any of the following: invasive mechanical ventilation, ECMO, cardiovascular organ support (balloon pump or inotropes/vasopressors), or renal failure (Cockcroft-Gault estimated creatinine clearance <15 ml/min, haemofiltration or dialysis). Note: participants qualifying under inclusion criterion 8b (pre-existing renal insufficiency or dialysis) are excluded only if they meet any of the other criteria (invasive mechanical ventilation, ECMO, or cardiovascular organ support). Participants who are physically located in an ICU or HDU but do not meet the above physiological criteria are not excluded on that basis alone
  • In the investigator's opinion, progression to death is imminent and inevitable irrespective of the provision of treatment
  • Pregnant women or nursing (breastfeeding) mothers

Ez a vizsgálat jelenleg itt érhető el: Bosznia-Hercegovina, Montenegró, Szerbia és Új-Zéland.

4 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

A clinical study to evaluate the efficacy and safety of once daily oral dosing of 100 mg AP1189 or placebo administered for 14 days, as an add-on to standard of care (SOC) in participants with respiratory insufficiency expected to be caused by respiratory viral infection.

A vizsgálat 2 csoportja

  • AP1189, 100 mgA vizsgált kezelés

    AP1189 tablet for oral use

  • AP1189 matching placeboA vizsgált kezelés

    AP1189 tablet for oral use

    Kezelés: Placebo

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Double-blind, Multicentre, Placebo-controlled, Proof-of-concept Clinical Trial Evaluating the Safety and Efficacy of the Biased Melanocortin Agonist AP1189 Versus Placebo as an add-on to Standard of Care (SOC) in Participants With RESPIRatory Insufficiency Expected to be Caused by Infection With Respiratory Viruses, Including Influenza, Respiratory Syncytial Virus, and Coronavirus
A regiszteradat frissítve
2026. július 28.